Bortezomib

Generic Name
Bortezomib
Brand Names
Velcade, Bortezomib Accord, Bortezomib Hospira, Bortezomib Fresenius Kabi, Bortezomib Sun
Drug Type
Small Molecule
Chemical Formula
C19H25BN4O4
CAS Number
179324-69-7
Unique Ingredient Identifier
69G8BD63PP
Background

Bortezomib is a dipeptide boronic acid derivative and proteasome inhibitor used to treat multiple myeloma and mantle cell lymphoma. The 26S proteasome is a protein complex that degrades ubiquitinated proteins in the ubiquitin-proteasome pathway: reversible inhibition of the 26S proteasome, leading to cell cycle arrest and apoptosis of cancer cells, is thought to be the main mechanism of action of bortezomib. However, multiple mechanisms may be involved in the anticancer activity of bortezomib.

Bortezomib was first synthesized in 1995. In May 2003, bortezomib became the first anticancer proteasome inhibitor that was approved by the FDA under the trade name VELCADE. Phase I, II, III, and IV clinical trials are undergoing to investigate the therapeutic efficacy of bortezomib in leukemia, myasthenia gravis, systemic lupus erythematosus, rheumatoid arthritis, and solid tumours.

Indication

Bortezomib is indicated for the treatment of adults with multiple myeloma or mantle cell lymphoma.

Associated Conditions
Mantle Cell Lymphoma (MCL), Multiple Myeloma (MM)
Associated Therapies
-
Clinical Trials
Related News

Study of Panobinostat in Combination With Bortezomib and Dexamethasone in Japanese Patients With Relapsed/Refractory Multiple Myeloma

First Posted Date
2014-11-14
Last Posted Date
2019-11-18
Lead Sponsor
Novartis Pharmaceuticals
Target Recruit Count
31
Registration Number
NCT02290431
Locations
🇯🇵

Novartis Investigative Site, Tokushima, Japan

A Pharmacokinetic Study of Bortezomib in Taiwanese Participants With Multiple Myeloma

Phase 4
Completed
Conditions
Multiple Myeloma
Interventions
Drug: Bortezomib
First Posted Date
2014-10-20
Last Posted Date
2016-07-11
Lead Sponsor
Johnson & Johnson Taiwan Ltd
Target Recruit Count
18
Registration Number
NCT02268890

An Open-Label Study of a Novel JAK-inhibitor, INCB052793, Given to Patients With Advanced Malignancies

First Posted Date
2014-10-16
Last Posted Date
2020-04-17
Lead Sponsor
Incyte Corporation
Target Recruit Count
83
Registration Number
NCT02265510
Locations
🇺🇸

Site 2, Nashville, Tennessee, United States

Safety/Efficacy Study of LDE225 (Sonidegib) Plus Bortezomib in Patients With Relapsed or Relapsed/Refractory Multiple Myeloma

Phase 2
Terminated
Conditions
Multiple Myeloma
Interventions
Drug: LDE225
Drug: Bortezomib
First Posted Date
2014-10-02
Last Posted Date
2017-02-16
Lead Sponsor
SCRI Development Innovations, LLC
Target Recruit Count
7
Registration Number
NCT02254551
Locations
🇺🇸

Colorado Blood Cancer Institute, Denver, Colorado, United States

🇺🇸

Oncology Hematology Care, Cincinnati, Ohio, United States

🇺🇸

Tennessee Oncology, Chattanooga, Tennessee, United States

and more 2 locations

Bendamustine Hydrochloride, Bortezomib, and Dexamethasone in Treating Patients With Newly Diagnosed Multiple Myeloma

First Posted Date
2014-08-25
Last Posted Date
2019-09-13
Lead Sponsor
Sidney Kimmel Cancer Center at Thomas Jefferson University
Target Recruit Count
24
Registration Number
NCT02224729
Locations
🇺🇸

Thomas Jefferson University, Philadelphia, Pennsylvania, United States

Dose Escalation of Velcade Daily Dose in Patients With Solid Tumors

Phase 1
Completed
Conditions
Advanced or Metastatic Solid Tumors
Interventions
Drug: Bortezomib
First Posted Date
2014-08-19
Last Posted Date
2016-03-25
Lead Sponsor
Gustave Roussy, Cancer Campus, Grand Paris
Target Recruit Count
18
Registration Number
NCT02220049
Locations
🇫🇷

Gustave Roussy, Villejuif, Val de Marne, France

Novel Approaches for Graft-versus-Host Disease Prevention Compared to Contemporary Controls (BMT CTN 1203)

First Posted Date
2014-08-04
Last Posted Date
2019-01-23
Lead Sponsor
National Heart, Lung, and Blood Institute (NHLBI)
Target Recruit Count
279
Registration Number
NCT02208037
Locations
🇺🇸

University of Florida College of Medicine (Shands), Gainesville, Florida, United States

🇺🇸

Virginia Commonwealth University MCV Hospitals, Richmond, Virginia, United States

🇺🇸

University of North Carolina Hospital at Chapel Hill, Chapel Hill, North Carolina, United States

and more 27 locations

Bortezomib in Rejection of Kidney Transplants

First Posted Date
2014-07-28
Last Posted Date
2020-09-16
Lead Sponsor
Assistance Publique - Hôpitaux de Paris
Target Recruit Count
60
Registration Number
NCT02201576
Locations
🇫🇷

Hopital Necker Enfants-malades, Paris, France

Nelfinavir as Bortezomib-sensitizing Drug in Patients With Proteasome Inhibitor-nonresponsive Myeloma

Phase 2
Completed
Conditions
Myeloma
Interventions
Drug: Nelfinavir
Drug: bortezomib
Drug: Dexamethasone
First Posted Date
2014-07-11
Last Posted Date
2019-06-26
Lead Sponsor
Swiss Group for Clinical Cancer Research
Target Recruit Count
34
Registration Number
NCT02188537
Locations
🇨🇭

Universitaetsspital-Basel, Basel, Switzerland

🇨🇭

Istituto Oncologico Svizzera Italiana IOSI, Bellinzona, Switzerland

🇨🇭

Hopital Fribourgeois, Fribourg, Switzerland

and more 9 locations

Study of Difluoromethylornithine (DFMO) in Combination With Bortezomib for Relapsed or Refractory Neuroblastoma

Phase 1
Completed
Conditions
Neuroblastoma Recurrent
Interventions
Drug: DFMO
Drug: Bortezomib
First Posted Date
2014-05-15
Last Posted Date
2024-08-06
Lead Sponsor
Giselle Sholler
Target Recruit Count
16
Registration Number
NCT02139397
Locations
🇺🇸

Connecticut Children's Hospital, Hartford, Connecticut, United States

🇺🇸

Arkansas Children's Hospital, Little Rock, Arkansas, United States

🇺🇸

Helen DeVos Children's Hospital, Grand Rapids, Michigan, United States

and more 3 locations
© Copyright 2024. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy